Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/19/2026, 12:00:00 AM
The U.S. FDA approved Wegovy HD, a new higher 7.2 mg dose of its weight-loss drug semaglutide. The approval was based on the STEP UP trial, which showed significant weight loss. The U.S. launch is expected in April 2026.
Korean Translation
미국 FDA, 체중 감량 약물 세마글루타이드의 새로운 고용량 버전인 위고비 HD(7.2mg)를 승인함. 이번 승인은 상당한 체중 감량 효과를 보인 STEP UP 임상시험에 근거한 것이며, 2026년 4월 미국 출시가 예상됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Expected FDA decision date for oral obesity drug orforglipron scheduled. High importance estimated as FDA decisions for major drugs typically cause >10% price swings.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
The ex-dividend date for the quarterly cash dividend of $1.25 per share is March 27, 2026, representing a 3% increase over the previous quarterly dividend.
3/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Annual General Meeting 2026 scheduled.
3/26/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
HSBC downgraded the stock from 'Hold' to 'Reduce' with a price target of $850, citing valuation concerns and competitive pressures.
3/22/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
Patents for semaglutide, the active ingredient in Ozempic and Wegovy, expired in key markets including China and India. This event opens the door to generic competition in those regions.
3/20/2026, 12:00:00 AM